The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Pfizer is looking to follow its vaccine ... comparison with placebo in older people at risk of RSV infections. The US Centres for Disease Control and Prevention (CDC) estimates that around 177,000 ...

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and labeled with anti-RSV F protein/gold ... Sales of both GSK’s and Pfizer’s vaccines for ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

Pfizer (NYSE:PFE) has decided not to further develop sisunatovir, an antiviral targeted at respiratory syncytial virus (RSV), ...

A new FDA approval has given Pfizer a ... for RSV immunisation to include older people, rather than younger populations. Last year, the US Centers for Disease Control and Prevention (CDC) Advisory ...

Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered in the fourth quarter. The product's sales fell 62% year over year to $198 ...

When applied to the Respiratory Syncytial Virus (RSV) F protein as a vaccine immunogen ... Calder's vaccine also demonstrates improvements in the quality of immune responses elicited since ...

Vincenza Snow, MD, Senior Director, Pfizer Medical Affairs joined us to talk about RSV today. RSV (respiratory syncytial virus) is a highly contagious respiratory virus, meaning it can spread ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...